AXPAXLI (axitinib intravitreal implant)

Neovascular age-related macular degeneration

Also known as OTX-TKI

Manufacturer: Ocular Therapeutix
Regulatory submission: NDA planned for the fourth quarter of 2026
Launch: Anticipated in 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description

Product information

124 evidence topics · 55 sources

Generic, brand name and therapeutic class of product5 evidence topics · 4 sources
Dosage forms and strengths5 evidence topics · 3 sources
American hospital formulary service (AHFS), or other drug classification2 evidence topics · 2 sources
Indication4 evidence topics · 4 sources
Pharmacology36 evidence topics · 18 sources
Contraindications/Warnings/Precautions/Adverse effects6 evidence topics · 6 sources
Special populations7 evidence topics · 5 sources
Drug/Drug, drug/disease interactions6 evidence topics · 3 sources
Dosing and administration11 evidence topics · 8 sources
Access and distribution7 evidence topics · 5 sources
Co-prescribed/Concomitant therapies7 evidence topics · 7 sources
Effect of axitinib intravitreal implant on quality measures2 evidence topics · 1 source
Product comparison26 evidence topics · 29 sources

Average sales price and wholesale acquisition cost

Not applicable.